Authors
Latest:
Unmet Needs of AML and Advice for Community OncologistsCourtney DiNardo, MD, concludes with discussing some challenges faced when treating patients with AML and shares some advice for community oncologists treating acute myeloid leukemia.
Latest:
Next Steps for Trastuzumab Emtansine After the KAMILLA TrialRachel Würstlein, MD, discusses the use of trastuzumab emtansine following the KAMILLA trial which evaluated the agent in patients with HER2-positive locally advanced or metastatic breast cancer who have brain metastases.
Latest:
Using ctDNA in Stage II Colon CancerCristian Tomasetti, discusses the role of circulating tumor-DNA after surgery in patients with stage II colon cancer.
Latest:
EP. 9A: The Rationale for CDK4/6 Inhibition in ES-SCLC and Updates on Trilaciclib Clinical Trial DataIn the fifth interview of the series, medical oncologist and hematologist Dr. Jerome H. Goldschmidt from Blue Ridge Cancer Care elaborates on the rationale for use of CDK4/6 inhibitors such as trilaciclib for prevention of chemotherapy-induced myelosuppression (CIM) in extensive-stage small cell lung cancer (ES-SCLC), and touches on recently presented data on trilaciclib.
Latest:
How Will New Immunotherapies Fit Into the Treatment Landscape of Follicular Lymphoma?Future directions for follicular lymphoma treatments include potential use earlier in treatment or as combination therapy, identifying patients who will benefit most from treatment, and minimizing the costs of therapy while maximizing accessibility.
Latest:
Expert Highlights Immunotherapy Advances in Lung Cancer Treatment LandscapeDavid M. Waterhouse, MD, MPH, shares advice with community oncologists treating patients with lung cancer.
Latest:
Kantarjian on Solutions for Oncology Drug ShortagesAccording to Hagop M. Kantarjian, MD, there are options for limited oncology drug shortages that require multi-sector involvement.
Latest:
Maintenance Niraparib Dose Modification Does Not Affect PFS in Ovarian CancerAmong patients with newly diagnosed, advanced ovarian cancer, dose modifications to frontline niraparib maintenance therapy did not affect progression-free survival.
Latest:
FLAURA Trial Demonstrates Efficacy in EGFR-Positive Lung CancerSuresh S. Ramalingam, MD, discusses the phase III FLAURA trial.
Latest:
Melanoma Monday: A Review of the MSLT-II Trial and Completion Lymph Node DissectionKatherine E. Poruk, MD, reviews the use of complete axillary lymph node dissection and the Multicenter Selective Lymphadenectomy Trial II for Melanoma Monday.
Latest:
Investigating Prognostic Markers for OS With LuPSMA Treatment in mCRPCAndrei Gafita, MD, discusses the overall survival in patients with metastatic castration-resistant prostate cancer who received 177Lutetium-prostate-specific membrane antigen radionuclide treatment.
Latest:
Biomarkers May Predict Outcomes With Specific Antibody Drug Conjugate for Urothelial Carcinoma TreatmentTumor mutation burden was linked with improved survival while some alterations were linked with inferior outcomes from treatment with enfortumab vedotin for urothelial carcinoma.
Latest:
Next Steps Using Anti-CD19 Therapies in DLBCLThe future of combined treatment approaches with anti-CD19 therapies for diffuse large B-cell lymphoma.
Latest:
Multikinase Inhibitor Options Flourish for Patients With RET-Mutant Medullary Thyroid CancerDuring a Targeted Oncology Case-Based Peer Perspectives event, Andrew G. Gianoukakis, MD, FACE, discussed the use of multikinase inhibitors for RET-mutated medullary thyroid cancer.
Latest:
Further Research Needed to Improve Outcomes in Advanced Ovarian CancerMelissa M. Hardesty discusses the key takeaways of the phase 2 OVARIO study of a PARP inhibitor plus a VEGF inhibitor in women with advanced ovarian cancer as well as research still needs to examine in this space.
Latest:
Kotecha Analyzes Use of 45 Gy Novel Radiotherapy in CNS CancersRupesh Kotecha, MD, discusses results of an analysis which centered around the use of pulse reduced dose rate intensity-modulated radiotherapy in patients with central nervous system malignancies.
Latest:
Roundtable Discussion: Addressing Management of Patients with Metastatic CRPC Following Frontline TreatmentsDuring a Targeted Oncology Case-Based Roundtable event, David I. Quinn, MD, PhD, MBBS leads a discussion on treatment for metastatic castration-resistant prostate cancer following frontline treatment.
Latest:
Future Treatment Approaches for HCCClosing out their discussion on the management of hepatocellular carcinoma, panelists discuss future novel therapies that may impact the treatment landscape.
Latest:
Hematology Workforce Shortage Poses Challenges for Cancer CareSrikanth Nagalla, MD, MS, describes initiatives to improve the talent pipeline for hematology staff at all levels.
Latest:
Immune Checkpoint to Watch: ICOSDeveloping modern strategies to predict and accurately monitor treatment response remains an important piece of the clinical management puzzle.
Latest:
Mitigating Toxicities Arising From Combination Therapies in RCCCombination therapy with checkpoint blockade, also termed immuno oncology agents, and multikinase tyrosine kinase inhibitors are rapidly becoming the first-line therapy of choice in patients with metastatic clear cell renal cell carcinoma.
Latest:
Gergis Explains the Differences Between Acute and Chronic GVHDUsama Gergis, MD, MBA, reviewed that difference in acute and chronic graft-versus-host disease and the treatment available for each
Latest:
The Importance of IMspire150 Data Is Questioned in Melanoma Treatment LandscapeCharles L. Sawyers, MD, discusses the value of atezolizumab, cobimetinib, and vemurafenib in the melanoma treatment landscape.
Latest:
Managing TKI-Related Adverse Events in RCCAn overview of adverse event and toxicity considerations with TKI therapies in renal cell carcinoma.
Latest:
PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 StudiesExpert perspectives on the PROfound and TRITON2 studies of olaparib and rucaparib, respectively, in metastatic castration-resistant prostate cancer.
Latest:
CheckMate 649 Study in GI Cancers Shows Survival Benefit for Nivolumab/ChemotherapyJaffer A. Ajani, MD, discusses the design and results of the CheckMate 649 study of nivolumab, ipilimumab, and chemotherapy for gastric cancers.
Latest:
Phase I/II Study Demonstrates Good Efficacy for Gastric CancerShuichi Hironaka, MD, PhD, discusses the efficacy of a phase I/II study of nivolumab, paclitaxel, and ramucirumab as second-line treatment of patients with advanced gastric cancer during the 2020 Gastrointestinal Cancers Symposium.
Latest:
Achieving Health Equity in Liver CancerPrimary liver cancer death rates vary by region, and much is still to be done in the area of health equity.
